NCT04369066: Curie-O-SA

COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur

Completed NA Last updated 23 September 2025

What this trial tests

NA trial testing Blood samples (collection of 5 mL of blood in a dry tube) in Volunteers From the Institute Curie and Institute Pasteur Staff Who Are Not Showing Active SARS-CoV-2 Infection in 1,971 participants. Completed in 13 May 2022.

Timeline

28 April 2020

Primary endpoint
6 January 2022

13 May 2022

Quick facts

Lead sponsor	Institut Curie
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	1,971
Start date	28 April 2020
Primary completion	6 January 2022
Estimated completion	13 May 2022
Sites	2 locations across France

Drugs / interventions tested

• Blood samples (collection of 5 mL of blood in a dry tube)
• Nasopharyngeal swabs — full drug profile →

Conditions studied

• Volunteers From the Institute Curie and Institute Pasteur Staff Who Are Not Showing Active SARS-CoV-2 Infection — all drugs for Volunteers From the Institute Curie and Institute Pasteur Staff Who Are Not Showing Active SARS-CoV-2 Infection →

Sponsor

Institut Curie — full company profile →

Who can join

18 and older, any sex, with Volunteers From the Institute Curie and Institute Pasteur Staff Who Are Not Showing Active SARS-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research proposes to study a large healthy population active for the presence of antibodies directed against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus and this over time.

After verification of the inclusion criteria and information by the coordinating investigative doctor, the volunteers sign a written consent. A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data.

The blood samples will be taken at 4 times for Institute Curie and Institute Pasteur: T0 (day of inclusion), between 6 weeks and 3 months ,6 months and 12 months post-inclusion.

Each blood sample consists of a collection of 5 mL of blood in a dry tube. The serum samples will be extracted and collected prospectively from the blood samples.

The nasopharyngeal swabs will be performed at 3 times: , between 6 weeks and 3 months, 6 months and 12 months post-inclusion for Institute Curie staff who have had at least one of the following four criteria on the sample or questionnaire carried out at T0:

* have had RT-PCR+
* and/or presence of antibodies at the 95% threshold
* and/or anosmia/ageusia
* and/or digestive syndrome with associated respiratory signs. In case of infection between sampling times, if the volunteer meets one of the four criteria above, a nasopharyngeal swab will be performed during the following visits.

The nasopharyngeal swab shall also be proposed to volunteers not meeting the 4 above listed criteria in order to have a control group (about 100 volunteers) for future statistical analyses.

If the volunteers accept, naso-pharyngeal swab shall be performed between 6 weeks and 3 months, 6 months and 12 months after inclusion.

For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) between 2 sampling times already planned in the flow chart, blood samples and nasopharyngeal swabs shall be performed.

Those shall be performed if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.

The blood samplings and nasopharyngeal swabs will be performed at 4 times for Institute Pasteur personnel: at T0 (inclusion day), between 6 weeks and 3 months, at 6 months and 12 months post-inclusion

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.
   Anna F, Goyard S, Lalanne AI, Nevo F, et al · · 2021 · cited 56× · PMID 33259646 · DOI 10.1002/eji.202049058
2. High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris
   Anna F, Goyard S, Lalanne AI, Nevo F, et al · · 2020 · cited 2× · DOI 10.1101/2020.10.25.20219030